SEC FORM
3
SEC Form 3
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
|
| OMB APPROVAL |
| OMB Number: |
3235-0104 |
| Estimated average burden |
| hours per response: |
0.5 |
|
|
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year)
10/31/2022
|
3. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC
[ MYGN ]
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
| X |
Director |
|
10% Owner |
|
Officer (give title below) |
|
Other (specify below) |
|
|
|
5. If Amendment, Date of Original Filed
(Month/Day/Year)
|
6. Individual or Joint/Group Filing (Check Applicable Line)
| X |
Form filed by One Reporting Person |
|
Form filed by More than One Reporting Person |
|
| Table I - Non-Derivative Securities Beneficially Owned |
|---|
| 1. Title of Security (Instr.
4)
|
2.
Amount of Securities Beneficially Owned (Instr.
4)
|
3. Ownership Form: Direct (D) or Indirect (I) (Instr.
5)
|
4. Nature of Indirect Beneficial Ownership (Instr.
5)
|
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
|
|---|
| 1. Title of Derivative Security (Instr.
4)
|
2. Date Exercisable and Expiration Date
(Month/Day/Year) |
3. Title and Amount of Securities Underlying Derivative Security (Instr.
4)
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form: Direct (D) or Indirect (I) (Instr.
5)
|
6. Nature of Indirect Beneficial Ownership (Instr.
5)
|
| Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
| Explanation of Responses: |
| Remarks: |
|
| No securities are beneficially owned. |
|
By: Justin Hunter For: Paul Bisaro |
11/01/2022 |
|
** Signature of Reporting Person |
Date |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
| * If the form is filed by more than one reporting person,
see
Instruction
5
(b)(v). |
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure. |
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |
POWER OF ATTORNEY
Know all by these presents, that the undersigned
hereby constitutes and appoints each of
R. Bryan Riggsbee, Pamela Wong, Natalie Munk,
and Justin Hunter of Myriad Genetics, Inc.
(the "Company"), signing singly, with
full power of substitution, the undersigned's true
and lawful attorney-in-fact to:
(1) execute for and on behalf of
the undersigned, in the undersigned's
capacity as an officer, director and/or
10% shareholder of the Company, Forms 3, 4
and 5 (and any amendments thereto) in
accordance with Section 16(a) of the Securities
Exchange Act of 1934, as amended
(the "Exchange Act"), and the rules thereunder;
(2) do and perform any and all acts for
and on behalf of the undersigned which may be
necessary or desirable to complete and execute
any such Form 3,4 or 5, complete and execute any
amendments thereto,and timely file such form
with the United States Securities and
Exchange Commission (the SEC) and any stock
exchange or similar authority, including without
limitation the filing of a Form ID or any other documents
necessary or appropriate to enable the
undersigned to file the Forms 3, 4 and 5
electronically with the SEC;
(3) seek or obtain, as the undersigned's representative
and on the undersigned's behalf, information on
transactions in the Company's securities from any third party,
including brokers, employee benefit plan administrators
and trustees, and the undersigned hereby authorizes
any such person to release any such information
to each of the undersigned's attorneys-in-fact appointed
by this Power of Attorney and approves and ratifies any
such release of information; and
(4) take any other action of any type whatsoever
in connection with the foregoing which, in the opinion
of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by,
the undersigned, it being understood that the documents
executed by such attorney-in-fact, on behalf of the
undersigned pursuant to this Power of Attorney,
shall be in such form and shall contain such terms
and conditions as such attorney-in-fact may
approve in such attorney-in-fact's discretion.
The undersigned hereby grants to each such
attorney-in-fact full power and authority to
do and perform any and every act and
thing whatsoever requisite, necessary,or
proper to be done in the exercise of any of
the rights and powers herein granted,
as fully to all intents and purposes as the
undersigned might or could do if personally present,
with full power of substitution or revocation,
hereby ratifying and confirming all that
such attorney-in-fact, or such attorney-in-fact's
substitute or substitutes, shall lawfully do or cause
to be done by virtue of this power of attorney and
the rights and powers herein granted. The
undersigned acknowledges that the foregoing
attorneys-in-fact, in serving in such capacity
at the request of the undersigned, is not assuming,
nor is the Company assuming, any of the
undersigned's responsibilities to comply with
Section 16 of the Exchange Act.
This Power of Attorney shall remain in
full force and effect until the undersigned
is no longer required to file Forms 3, 4
and 5 with respect to the undersigned's
holdings of and transactions in securities
issued by the Company, unless earlier revoked
by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned
has caused this Power of Attorney to
be executed this 30th day of October, 2022.
/S/ Paul Bisaro
Paul Bisaro
